基于血红蛋白和贫血症状的决策方案实施后输血成本降低:前后分析

IF 3.1 4区 医学 Q1 Medicine Medical Science Monitor Pub Date : 2024-12-04 DOI:10.12659/MSM.945854
Piotr F Czempik, Jan Herzyk, Dawid Wilczek, Anna Rogalska
{"title":"基于血红蛋白和贫血症状的决策方案实施后输血成本降低:前后分析","authors":"Piotr F Czempik, Jan Herzyk, Dawid Wilczek, Anna Rogalska","doi":"10.12659/MSM.945854","DOIUrl":null,"url":null,"abstract":"<p><p>BACKGROUND Blood products are an expensive resource. The study aimed to assess the cost spent on red blood cell (RBC) transfusions before and after implementing a 2-factorial RBC transfusion decision protocol and the current cost of an RBC transfusion procedure in the local healthcare system. MATERIAL AND METHODS Six-month periods before and after the implementation of the decision protocol were compared. The cost components considered included RBCs, laboratory tests, labor of healthcare workers involved in the procedure, and management of transfusion reactions. RESULTS Following the implementation of the decision protocol, there was a decrease in transfusion costs by €51,411 (56.4%) in our low transfusion rate setting. Inappropriate RBC transfusions amounted to €25,0146 (62.9% of all transfusions costs). The cost of a leucodepleted RBC transfusion increased in the periods being compared, from approximately €109 to €126 in the local healthcare system. CONCLUSIONS Implementing an RBC transfusion decision protocol based on a 2-factorial approach can lead to a more than 2-fold reduction in cost spent on RBC transfusions in a low transfusion rate setting. Even after the implementation of the protocol, further education of clinicians is required, as there may still be potential to reduce costs associated with inappropriate transfusions. The non-RBC acquisition cost of an RBC transfusion procedure approximates the cost of a blood component itself in the local healthcare system.</p>","PeriodicalId":48888,"journal":{"name":"Medical Science Monitor","volume":"30 ","pages":"e945854"},"PeriodicalIF":3.1000,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11626835/pdf/","citationCount":"0","resultStr":"{\"title\":\"Cost Reduction in Blood Transfusions After Implementation of Decision Protocol Based on Hemoglobin and Anemia Symptoms: A Pre-Post Analysis.\",\"authors\":\"Piotr F Czempik, Jan Herzyk, Dawid Wilczek, Anna Rogalska\",\"doi\":\"10.12659/MSM.945854\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>BACKGROUND Blood products are an expensive resource. The study aimed to assess the cost spent on red blood cell (RBC) transfusions before and after implementing a 2-factorial RBC transfusion decision protocol and the current cost of an RBC transfusion procedure in the local healthcare system. MATERIAL AND METHODS Six-month periods before and after the implementation of the decision protocol were compared. The cost components considered included RBCs, laboratory tests, labor of healthcare workers involved in the procedure, and management of transfusion reactions. RESULTS Following the implementation of the decision protocol, there was a decrease in transfusion costs by €51,411 (56.4%) in our low transfusion rate setting. Inappropriate RBC transfusions amounted to €25,0146 (62.9% of all transfusions costs). The cost of a leucodepleted RBC transfusion increased in the periods being compared, from approximately €109 to €126 in the local healthcare system. CONCLUSIONS Implementing an RBC transfusion decision protocol based on a 2-factorial approach can lead to a more than 2-fold reduction in cost spent on RBC transfusions in a low transfusion rate setting. Even after the implementation of the protocol, further education of clinicians is required, as there may still be potential to reduce costs associated with inappropriate transfusions. The non-RBC acquisition cost of an RBC transfusion procedure approximates the cost of a blood component itself in the local healthcare system.</p>\",\"PeriodicalId\":48888,\"journal\":{\"name\":\"Medical Science Monitor\",\"volume\":\"30 \",\"pages\":\"e945854\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2024-12-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11626835/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Science Monitor\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.12659/MSM.945854\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Science Monitor","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12659/MSM.945854","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

血液制品是一种昂贵的资源。该研究旨在评估在实施2因子红细胞输血决策方案之前和之后红细胞(RBC)输血的成本以及当地医疗系统中红细胞输血程序的当前成本。材料与方法比较决策方案实施前后6个月的情况。考虑的成本组成部分包括红细胞、实验室检测、参与手术的医护人员的劳动力以及输血反应的管理。结果执行决策方案后,在我们的低输血率设置中,输血成本降低了51,411欧元(56.4%)。不适当的红细胞输血达25,0146欧元(占所有输血费用的62.9%)。在比较期间,在当地医疗保健系统中,低白细胞红细胞输血的费用从大约109欧元增加到126欧元。结论:在低输血率环境下,实施基于2因子方法的红细胞输血决策方案可使红细胞输血成本降低2倍以上。即使在实施该方案之后,仍需要对临床医生进行进一步教育,因为仍有可能降低与不适当输血相关的费用。在当地的医疗保健系统中,红细胞输血过程的非红细胞获取成本近似于血液成分本身的成本。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Cost Reduction in Blood Transfusions After Implementation of Decision Protocol Based on Hemoglobin and Anemia Symptoms: A Pre-Post Analysis.

BACKGROUND Blood products are an expensive resource. The study aimed to assess the cost spent on red blood cell (RBC) transfusions before and after implementing a 2-factorial RBC transfusion decision protocol and the current cost of an RBC transfusion procedure in the local healthcare system. MATERIAL AND METHODS Six-month periods before and after the implementation of the decision protocol were compared. The cost components considered included RBCs, laboratory tests, labor of healthcare workers involved in the procedure, and management of transfusion reactions. RESULTS Following the implementation of the decision protocol, there was a decrease in transfusion costs by €51,411 (56.4%) in our low transfusion rate setting. Inappropriate RBC transfusions amounted to €25,0146 (62.9% of all transfusions costs). The cost of a leucodepleted RBC transfusion increased in the periods being compared, from approximately €109 to €126 in the local healthcare system. CONCLUSIONS Implementing an RBC transfusion decision protocol based on a 2-factorial approach can lead to a more than 2-fold reduction in cost spent on RBC transfusions in a low transfusion rate setting. Even after the implementation of the protocol, further education of clinicians is required, as there may still be potential to reduce costs associated with inappropriate transfusions. The non-RBC acquisition cost of an RBC transfusion procedure approximates the cost of a blood component itself in the local healthcare system.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Medical Science Monitor
Medical Science Monitor MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
6.40
自引率
3.20%
发文量
514
审稿时长
3.0 months
期刊介绍: Medical Science Monitor (MSM) established in 1995 is an international, peer-reviewed scientific journal which publishes original articles in Clinical Medicine and related disciplines such as Epidemiology and Population Studies, Product Investigations, Development of Laboratory Techniques :: Diagnostics and Medical Technology which enable presentation of research or review works in overlapping areas of medicine and technology such us (but not limited to): medical diagnostics, medical imaging systems, computer simulation of health and disease processes, new medical devices, etc. Reviews and Special Reports - papers may be accepted on the basis that they provide a systematic, critical and up-to-date overview of literature pertaining to research or clinical topics. Meta-analyses are considered as reviews. A special attention will be paid to a teaching value of a review paper. Medical Science Monitor is internationally indexed in Thomson-Reuters Web of Science, Journals Citation Report (JCR), Science Citation Index Expanded (SCI), Index Medicus MEDLINE, PubMed, PMC, EMBASE/Excerpta Medica, Chemical Abstracts CAS and Index Copernicus.
期刊最新文献
Linear Dimensional Accuracy in Maxillomandibular Records: A Comparative Study of Scannable and Transparent Materials. Long-Term Outcomes of Implanon in Managing Adenomyosis: A 3-Year Prospective Study. Predicting Cerebral Small Vessel Disease Burden Based on Thromboelastography in Patients with Acute Ischemic Stroke: A Pilot Study. Procedure Dynamics in Transfemoral vs Transradial Cerebral Angiography: A Retrospective Study. Retracted: IC-2 Suppresses Proliferation and Induces Apoptosis of Bladder Cancer Cells via the Wnt/β-Catenin Pathway.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1